U.S. pharmaceutical giant Eli Lilly on the 12th received China’s first marketing approval for orforglipron, an oral GLP-1 receptor agonist for treating obesity. The move puts Lilly ahead of Denmark’s Novo Nordisk and kicks off a battle for dominance in China, the world’s second-largest pharmaceutical market.

Until now, only injectable GLP-1 obesity drugs had been available in China. The arrival of an oral option is expected to help capture patients who are reluctant to use injections. Lilly declined to comment on pricing or launch timing in China following the approval.

Novo Nordisk has also applied for marketing approval in China for an oral version of its obesity drug Wegovy but has not yet received it. Lilly’s decision to file first with orforglipron gave it the lead. In the Chinese market, once-weekly GLP-1 injections from Novo Nordisk, U.S.-based Pfizer and local heavyweight Innovent Biologics are competing for share.

Yang Huang, JPMorgan’s head of China healthcare research, forecasts that annual sales of GLP-1 drugs for weight loss in China could rise from an estimated CNY 3 billion to CNY 4 billion (approximately $449.7 million to $599.8 million) currently to CNY 30 billion (approximately $4.5 billion) over the next five to seven years. China’s National Health Commission projects that the share of overweight and obese people will exceed 65% by 2030.

The oral drug’s approval gives Lilly more room to expand its China business. The company’s shares rose 2.8% in U.S. after-hours trading following reports of the approval.

According to a press release, Lilly also signed a strategic partnership with Swiss pharmaceutical giant Richter focused on estetrol (E4) in women’s health and cardiometabolic disease. Lilly will acquire global rights to develop E4 combination products and an option to co-commercialize FYLREVY in the United States. Richter will receive supply economics for E4 as well as milestone payments and royalties. Lilly plans to acquire approximately $15 million of Richter’s ordinary shares from its own treasury stock.

In China’s obesity drug market, the approval of an oral treatment could reshape a competitive landscape that has been dominated by injectables. The timing of approval for Novo Nordisk’s oral Wegovy will be the focus going forward.